Brief: Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation For The Treatment Of Sortilin-Expressing Cancers

Theratechnologies

04/02/2021 12:51

Feb 4 (Reuters) - Theratechnologies Inc  TH.TO :
    * THERATECHNOLOGIES’ LEAD PEPTIDE DRUG CONJUGATE TH1902
RECEIVES
FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF
SORTILIN-EXPRESSING CANCERS

Source text for Eikon:  ID:nGNX7Y9hh6 
Further company coverage:  TH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))